Showing results (291-300 of 298) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 298 results.
Acta Pharmaceutica Sinica. B|August 15, 2022
Schaftoside inhibits 3CLpro and PLpro of SARS-CoV-2 virus and regulates immune response and inflammation of host cells for the treatment of COVID-19Yang Yi, Meng Zhang, Heng Xue, et al.
Journal of Pharmaceutical Analysis|June 26, 2023
Licorice-saponin A3 is a broad-spectrum inhibitor for COVID-19 by targeting viral spike and anti-inflammationYang Yi, Wenzhe Li, Kefang Liu, et al.
ACS Central Science|January 30, 2019
Principles of Inter-Amino-Acid Recognition Revealed by Binding Energies between Homogeneous OligopeptidesHuiwen Du, Xiaoyu Hu, Hongyang Duan, et al.
Frontiers in Immunology|August 19, 2021
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort StudyJiao Liu, Yanfei Shen, Zhenliang Wen, et al.
Annals of Intensive Care|August 7, 2022
Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control studyJiao Liu, Min Shao, Qianghong Xu, et al.
Nature Communications|August 27, 2024
RNA nanotherapeutics with fibrosis overexpression and retention for MASH treatmentXinzhu Shan, Zhiqiang Zhao, Pingping Lai, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 21, 2005
Dysregulation of TGF-beta1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient miceXiangchun Wang, Shinya Inoue, Jianguo Gu, et al.
The Lancet Regional Health. Western Pacific|February 13, 2023
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled studyJiao Liu, Xiaojun Pan, Sheng Zhang, et al.
Pageof 30